Asia Pacific Drug Screening Market

APAC Drug Screening Market Size (2024 to 2029)

The size of the Asia-Pacific Drug Screening Market is valued at USD 1.27 billion in 2024. It is expected to grow at a CAGR of 10.8% to approach USD 2.12 billion by 2029.

Drug screening, otherwise known as drug testing, is performed in various cases, such as when patients are unconscious and cannot tell what drug they have taken earlier. Drug tests are also done for patients to identify which drugs they are allergic to and in cases of known drug allergic conditions with pain management. The testing process involves collecting various samples, including skin, hair follicles, blood, saliva, and urine.

Various factors, including increased population, increased medicine, healthcare, infrastructure, rise in chronic diseases, and rise in intake of drugs by patients, contribute to the growth of the drug screening market. The increase in patients who are allergic to some compositions of drugs also increases market size. For various religious reasons, the ban on substances and drugs is seen. For instance, different Indian regions follow some religious practices where the intake of the drug is considered a sin. In such cases, the drug screening process is performed in terms of substance abuse. People in this region are more aware of drug screening policy increases market size. Growing demand for safety rules and regulations in every place and increasing drug, alcohol, and substance abuse are significant growth driving factors for the drug screening market in developed regions like India, China, and other parts of Asia. Government initiatives for a ban on drugs of abuse and an increase in fundraising activities and awareness of healthy lifestyle activities positively impact the market and increase the market growth.

However, factors such as masking agents' availability to mask drug screening tests are a significant concern for drug screening tests. According to a few regional authorities, drug testing, or drug screening in those particular regions is considered against their privacy policies and violations. Many devices like alcohol screening devices and other devices used in the process of drug testing; should meet standards set up by approval committees. A lot of accuracy issues are noted in recent times for these devices. Devices such as breath analyzers, sample collection devices need to be available at the right time, and these devices' functioning is to be adequately checked to avoid errors in testing.

COVID-19 impact: 

The ongoing COVID pandemic has shown harsh effects on every other market, likewise the drug screening market. During the outbreak of COVID, there are many travel ban issues and lockdown regulations to prevent the spread of the virus. Due to the government's stringent rules and regulations due to lockdown, and as people's movement is restricted, most people being youth and old aged are driven for alcohol consumption and drug abuse across this region. There is a lack of skilled workers and staff for various clinics, hospitals, and diagnostic centers. Hence this affected market in a huge scenario. Due to various drug abuse and substance intake, people who have withdrawal symptoms faced difficulties due to insufficient resources. For instance, people who wanted to get drug-screened or tested could not get in touch with healthcare workers as they got indulged in COVID healthcare schemes and regulations.

This research report on the Asia-Pacific Drug Screening Market has been segmented and sub-segmented into the following categories:

• By Sample Type: Hair, Blood, Urine, and Others
• By End-user: Hospitals, Workplaces, Criminal Justice and Law Enforcement
• By Products And Services: Breathalyser, Rapid Test Device, Immunoassay Analyser, Chromatography, and Others
• By Country: India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore, and Rest of APAC

Regional Analysis:

The Asia-Pacific regions consist of big and developing countries like India and China. The area is characteristic of increasing levels of personal disposable income. It is making many people subscribe to the usage and abuse of several illegal substances in the area. It is the chief factor behind the very high projected CAGR for the market in the future.

The drug screening market in the Asia Pacific region is further expecting a hike due to various factors such as a rise in patients who are allergic to some compositions of drugs, increased population, increased medicine, and healthcare, infrastructure, an increase of chronic diseases, and a rise in intake of drugs by patients. India and China are the regions with the highest market revenue amongst Asia pacific regions. This due to the highest population, increased substance, and drug abuse in these regions.

The Top companies leading in the APAC Drug Screening Market profiled in the report are Thermo Fisher Scientific Inc., Express Diagnostics Int’l Inc., Abbott Laboratories, Siemens AG, Alere Inc., Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, Biorad Laboratories Inc., Shimadzu and Omega Laboratories.